Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Dr Serena Lucotti, who has been awarded 'Italy Made Me' prize for her DPhil project.

Dr Serena Lucotti, a postdoctoral researcher in the Mechanisms of Metastasis research group, has been awarded an Italy Made Me prize for her DPhil project entitled: ‘Targeting prostanoid biosynthesis during metastasis: the therapeutic potential of aspirin and beyond’.

During her DPhil, Serena studied the effect of aspirin and other anti-platelet drugs on cancer metastasis, which led her to discover a novel platelet signalling pathway that supports tumour cell dissemination through the bloodstream. Her work identifies new targets and therapeutic opportunities for the prevention of metastasis in cancer patients.

Serena received her award from the Ambassador, Raffaele Trombetta, at a ceremony at the Italian Embassy on 4th September. 

The Italy Made Me award recognises UK-based Italian researchers who received part of their training in Italy. There are prizes for innovative research in three categories: Life Sciences, Physical and Engineering Sciences, Social Sciences and Humanities. It is coordinated by the Italian Embassy in London, in collaboration with Il Circolo, the “Association of Italian Scientists in the United Kingdom” (AISUK) and other Italian academic associations in the UK.

Similar stories

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Mark Hill becomes Fellow of the Institute of Physics and Engineering in Medicine

Dr Mark Hill was awarded the honour of Fellow of the Institute of Physics and Engineering in Medicine (FIPEM) after ‘demonstrating scientific and professional attainment of outstanding merit’.

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.